Crystal structure and improved antisense properties of 2'-O-(2- methoxyethyl)-RNA

被引:0
|
作者
Teplova M. [1 ]
Minasov G. [1 ]
Tereshko V. [1 ]
Inamati G.B. [1 ]
Cook P.D. [1 ]
Manoharan M. [1 ]
Egli M. [1 ]
机构
[1] Department of Medicinal Chemistry, Isis Pharmaceuticals Inc., Carlsbad
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
D O I
10.1038/9304
中图分类号
学科分类号
摘要
2'-O-(2-Methoxyethyl)-RNA (MOE-RNA) is a nucleic acid analog with promising features for antisense applications. Compared with phosphorothioate DNA (PS-DNA), the MOE modification offers improved nuclease resistance, enhanced RNA affinity, improved cellular uptake and intestinal absorption, reduced toxicity and immune stimulation. The crystal structure of a fully modified MOE-RNA dodecamer duplex (CGCGAAUUCGCG) was determined at 1.7 Å resolution. In the majority of the MOE substituents, the torsion angle around the ethylene alkyl chain assumes a gauche conformation. The conformational preorganization of the MOE groups is consistent with the improved RNA affinity and the extensive hydration of the substituents could play a role in the improved cellular uptake of MOE-RNA. A specific hydration pattern that bridges substituent and phosphate oxygen atoms in the minor groove of MOE- RNA may explain its high nuclease resistance.
引用
收藏
页码:535 / 539
页数:4
相关论文
共 50 条
  • [1] Crystal structure and improved antisense properties of 2′-O-(2-methoxyethyl)-RNA
    Teplova, M
    Minasov, G
    Tereshko, V
    Inamati, GB
    Cook, PD
    Manoharan, M
    Egli, M
    NATURE STRUCTURAL BIOLOGY, 1999, 6 (06): : 535 - 539
  • [2] Comparing in vitro and in vivo activity of 2′-O-[2-(methylamino)-2-oxoethyl]- and 2′-O-methoxyethyl-modified antisense oligonucleotides
    Prakash, Thazha P.
    Kawasaki, Andrew M.
    Wancewicz, Edward V.
    Shen, Lijiang
    Monia, Brett P.
    Ross, Bruce S.
    Bhat, Balkrishen
    Manoharan, Muthiah
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (09) : 2766 - 2776
  • [3] Metabolism and Disposition of Volanesorsen, a 2′-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species
    Post, Noah
    Yu, Rosie
    Greenlee, Sarah
    Gaus, Hans
    Hurh, Eunju
    Matson, John
    Wang, Yanfeng
    DRUG METABOLISM AND DISPOSITION, 2019, 47 (10) : 1164 - 1173
  • [4] Conversion of uridine into 2′-O-(2-methoxyethyl)uridine and 2′-O-(2-methoxyethyl)cytidine
    Legorburu, U
    Reese, CB
    Song, QL
    TETRAHEDRON, 1999, 55 (17) : 5635 - 5640
  • [5] Synthesis and evaluation of antisense properties of 2′-O-[2-(methylthio)ethyl]-RNA:: Favorable protein binding characteristics.
    Prakash, TP
    Manoharan, M
    Fraser, AS
    Kawasaki, AM
    Lesnik, EA
    Sioufi, N
    Leeds, JM
    Egli, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 222 : U165 - U165
  • [6] Diastereomeric process control in the synthesis of 2'-O-(2-methoxyethyl) oligoribonucleotide phosphorothioates as antisense drugs
    Ravikumar, VT
    Cole, DL
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2003, 22 (5-8): : 1639 - 1645
  • [7] Synthesis and Antisense Properties of 2′-O-(2S-Methoxypropyl)-RNA-Modified Gapmer Antisense Oligonucleotides
    Yu, Jinghua
    Pandey, Sanjay K.
    Khatri, Hetal
    Prakash, Thazha P.
    Swayze, Eric E.
    Seth, Punit P.
    CHEMMEDCHEM, 2014, 9 (09) : 2040 - 2044
  • [8] 2′-O-[2-(methylthio)ethyl]-modified oligonucleotide:: An analogue of 2′-O-[2-(methoxy)-ethyl]-modified oligonucleotide with improved protein binding properties and high binding affinity to target RNA
    Prakash, TP
    Manoharan, M
    Kawasaki, AM
    Fraser, AS
    Lesnik, EA
    Sioufi, N
    Leeds, JM
    Teplova, M
    Egli, M
    BIOCHEMISTRY, 2002, 41 (39) : 11642 - 11648
  • [9] NMR structure of 2′-O-(2-methoxyethyl) modified and C5-methylated RNA dodecamer duplex
    Plevnik, Miha
    Cevec, Mirko
    Plavec, Janez
    BIOCHIMIE, 2013, 95 (12) : 2385 - 2391
  • [10] Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats
    Geary, RS
    Khatsenko, O
    Bunker, K
    Crooke, R
    Moore, M
    Burckin, T
    Truong, L
    Sasmor, H
    Levin, AA
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2001, 296 (03): : 898 - 904